Drug treats hepatitis C by targeting body's RNA

03/27/2013 | Science News

A new drug for hepatitis C attacks RNA that allows the virus to hide from the immune system. The drug, miravirsen, targets the body's microRNA-122, preventing viral replication, according to findings published in the New England Journal of Medicine. The treatment could potentially be used in other serious diseases, including cancer. "This is really a revolution in science, and it's now beginning to be translated into advances that control disease," said Phillip Sharp, an MIT molecular biologist who won a 1993 Nobel Prize for research on RNA.

View Full Article in:

Science News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director Quality Improvement
Molina Healthcare of Texas
San Antonio, TX
Senior Medical Director
Network Health
Medford, MA
SVP/Head of Health Plans and Managed Care
Avalere Health
Washington, DC
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
PacificSource
Bend, OR